BETA SITE | REPORT ISSUES / GIVE FEEDBACK

Letters (Westmoreland)

Letter to the editor: Cost of covid treatment evidence of drug companies’ gouging

Tribune-Review
By Tribune-Review
1 Min Read Jan. 3, 2025 | 1 year Ago
Go Ad-Free today

A few months ago, a friend of mine contracted covid. Soon after, her medical insurance company issued a statement stating they had paid the drug company $1,453.55 for the Paxlovid treatment. The high cost of the antiviral was a little concerning, and I decided to do some research into the situation. Here are my findings.

The National Institutes of Health received billions of dollars to fund the research and development of treatments for covid. Those dollars came from taxes paid by you, the American taxpayer.

The drug company’s production cost is $13.38. The cost to you, the consumer, is $1,390 to $1,455, a 100-times mark-up.

How did the drug industry use those massive profits? The large drug company CEOs’ compensation is in the tens of millions of dollars yearly. The drug industry further enriches the CEOs and shareholders by spending billions on stock buybacks. The industry spends more on stock buybacks than on research and development.

The industry also spends billions of dollars in advertising and billions of dollars on lobbying. The pharmaceutical companies use their excess profits from price gouging us to legally bribe our lawmakers to work for them instead of us, their constituents.

It is time for us to demand a change.

Gloria Gralewski

Manor

Share

Tags:

About the Writers

Push Notifications

Get news alerts first, right in your browser.

Enable Notifications

Content you may have missed

Enjoy TribLIVE, Uninterrupted.

Support our journalism and get an ad-free experience on all your devices.

  • TribLIVE AdFree Monthly

    • Unlimited ad-free articles
    • Pay just $4.99 for your first month
  • TribLIVE AdFree Annually BEST VALUE

    • Unlimited ad-free articles
    • Billed annually, $49.99 for the first year
    • Save 50% on your first year
Get Ad-Free Access Now View other subscription options